Blockade of SUR1 receptors with glibenclamide has been involved in improved outcome in animal stroke models and investigational human studies by preventing brain swelling and enhancing neuroprotection.
Using glibenclamide to block SUR1 receptors has been found beneficial in both animal stroke studies and early-stage human trials, as it helps prevent brain swelling and enhances the effectiveness of neuroprotective measures.